Interleukin 6 News and Research

RSS

Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.

E484K mutation may confer immune evasion capability on UK variant of SARS-CoV-2

A new medRxiv* preprint reports the immunomodulatory effect of the E484K mutation newly acquired by the United Kingdom (U.K.) variant.

2 Jun 2021

Large-scale expansion of spike-reactive T cells feasible after COVID-19 vaccination

A new bioRxiv* preprint reports on the successful use of a protocol to expand SARS-CoV-2-reactive T-cells a thousand-fold.

2 Jun 2021

Can depression increase the likelihood of rapid kidney function decline?

In a recent study, the presence of depressive symptoms in normally healthy individuals was found to correlate with rapid kidney function decline.

1 Jun 2021

SARS-CoV-2 NSP14 induces potent inflammation via NF-κB pathways, finds study

SARS-CoV-2 has a single-stranded RNA genome encoding both structural and non-structural proteins. Of these, the latter is known to play a variety of roles in viral replication and the assembly of new viral particles, as well as in suppressing cellular immune responses. A new study reports the activity of one such protein, the non-structural protein 14 (NSP14), which activates the inflammatory mediator NF-κB to trigger intense inflammation.

31 May 2021

Inflammatory brain injury higher in men with acute COVID-19, finds study

The COVID-19 pandemic has been associated with both short- and long-term neurologic complications, including stroke, brain fog and persistent tiredness. A new study concludes that the effects of SARS-CoV-2 on the central nervous system (CNS) are due to the endothelial injury and inflammation that this produces in the brain.

31 May 2021

Study links barotrauma to COVID-19 in younger patients

To better understand the possible relationship between severe infection and poor in-hospital outcomes, researchers from the Internal Medicine, and the Pulmonary Critical Care Medicine, Rutgers University, Newark, USA, presented a case series linking barotrauma to COVID-19 in younger patients.

28 May 2021

Vagus nerve stimulation may be a potential adjunct therapy for COVID-19

COVID-19 was initially described as lung inflammation, or pneumonia, in older adults. However, we now know that SARS-CoV-2 infections can cause a wide range of symptoms in people of all ages, ranging from no symptoms at all to systemic inflammation and even death.

27 May 2021

The potential therapeutic value of CDK6 inhibitors in critical COVID-19

While drug repurposing has been explored in the context of the current coronavirus disease 2019 (COVID-19) pandemic, the success of this strategy has been limited so far. A new study, released as a preprint on the medRxiv* server, describes a new method of identifying a promising hit among drugs already in use.

24 May 2021

Research suggests Garcinia kola extract might suppress severe COVID-19 cytokine storms

Researchers in the UK and Nigeria have conducted a study showing that Garcinia kola seed extract and garcinoic acid may provide therapeutic benefits in the late stage of severe coronavirus disease 2019 (COVID-19) and other coronavirus infections.

24 May 2021

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

Toll-like receptor 2 (TLR2) detects the SARS-CoV-2 envelope protein and generates inflammatory cytokines

Researchers at St Jude Children’s Research Hospital found that toll-like receptor 2 detects the SARS-CoV-2 envelope protein-producing inflammatory cytokines.

19 May 2021

Higher levels of inflammatory proteins in the blood are associated with aggressive traits

Aggression is common in many neuropsychiatric diseases, such as dementia, autism spectrum disorder, and schizophrenia.

18 May 2021

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

A team of scientists from the USA and Belgium has recently revealed that the ErbB family of receptor tyrosine kinases play a vital role in regulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lifecycle in host cells and that inhibition of these receptors can protect against SARS-CoV-2-induced acute and chronic lung injuries and inflammation.

18 May 2021

Certain immune cells unexpectedly change their behavior to cause psoriasis lesions

Millions of people suffer from psoriasis, a chronic, autoimmune disorder that causes scaly patches on the skin and often precedes psoriatic arthritis. While no cure exists, treatments range from topical creams to injected medications that block inflammation.

13 May 2021

Research provides new insight into anesthesia-associated tau spreading in the brain

During the development and progression of Alzheimer's disease, a protein called tau accumulates and spreads in the brain.

12 May 2021

Study reveals acute immunologic changes in children with long COVID

Many reports are beginning to emerge on the ‘long COVID’ phenomenon. But a new study, released as a preprint on the medRxiv* server, describes, for the first time, immunologic changes observed in children with PASC.

11 May 2021

Case study describes consequences of undetected SARS-CoV-2 infection during mRNA vaccination

Now, a new report describes a case of a coincidental mRNA vaccination and SARS-CoV-2 infection in a 31-year-old doctor, addressing the theoretical considerations for potential risks and further required actions in case more cases appear in the future.

11 May 2021

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Researchers in The Netherlands have warned that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces complex reprogramming of innate immune responses that should be considered in the development and use of mRNA-based vaccines.

10 May 2021

Are infants at greater risk of COVID-19 than children?

The widely circulating SARS-CoV-2 has caused the devastating COVID-19 pandemic. The impact of this infection varies significantly with age, sparing young children for the most part, though not completely. However, a new study, released as a preprint on the medRxiv* server, shows that infants are not as resistant to the virus as children are. The researchers trace this to the expression of ACE2 to varying extents in different groups.

7 May 2021

Transplant recipients with COVID-19 may show lower cellular and antibody immune responses

Transplant patients are typically on chronic immunosuppression, making them automatically more vulnerable to infection with SARS-CoV-2, the agent responsible for the loss of over three million lives in the current COVID-19 pandemic. A new study discusses evidence for subnormal immune responses following COVID-19 in this population.

6 May 2021